A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2037-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy,
ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.